RxDoctor Payments Data

Alfredo Dosdos, MD

Internal Medicine · Atlantis, FLNPI 1427004548

Payments from drug & device makers

$1,631in general payments, 2019–2025

Across 89 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$200
  • Pfizer$165
  • Astellas Pharma US Inc$151
  • Novo Nordisk$143
  • Amarin Pharma, Inc.$127
  • AbbVie$122
  • plus $723 from 20 others

What the payments were for

  • Food & beverage$1,631100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,631 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$180,801
Medicare patients
451
Services billed
2,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$118,902
EliquisApixaban69$69,864
JardianceEmpagliflozin37$49,153
XareltoRivaroxaban32$41,230
JanuviaSitagliptin Phosphate19$31,151
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$26,264
FarxigaDapagliflozin Propanediol24$21,930
MounjaroTirzepatide14$14,406
MyrbetriqMirabegron14$13,758
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,247
SymbicortBudesonide/Formoterol Fumarate36$8,905
Breo ElliptaFluticasone/Vilanterol23$7,700
Atorvastatin Calcium687$6,197
Levothyroxine Sodium633$6,107
Rosuvastatin Calcium439$5,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$143$118,90277 claims
PfizerEliquis$165$69,86469 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$45$42,08278 claims
Johnson & JohnsonXarelto$89$41,23032 claims
GSKTrelegy Ellipta, Breo Ellipta$48$33,96362 claims
MerckJanuvia$61$31,15119 claims
Lilly USA, LLCMounjaro$18$14,40614 claims
Astellas Pharma US IncMyrbetriq$151$13,75814 claims
AbbVieSynthroid$122$4,64165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →